admin

Fatty Liver Disease a Long-COVID Symptom After Severe Cases?

by admin | Jan 11, 2022 | Clinical Manifestations, Epidemiology

Sorry, this entry is only available in 中文.類型: 連結作者: Zaina Hamza 出處: MedPage Today 連結:...

‘Killer’ immune cells still recognize Omicron variant

by admin | Jan 11, 2022 | Virology, Pathophysiology

Sorry, this entry is only available in 中文.類型: 連結作者: Heidi Ledford 出處: Nature 連結:...

Country shatters records with 1.35 million daily Covid cases

by admin | Jan 11, 2022 | Medical Health, Facility Staff, Medications

Sorry, this entry is only available in 中文.類型: 連結作者: RT 出處: RT 連結:...

Senators Press Administration Officials on COVID Test Availability

by admin | Jan 11, 2022 | Breaking News Express-CP

Sorry, this entry is only available in 中文.類型: 連結作者: Joyce Frieden 出處: MedPage Today 連結:...

Omicron-specific vaccines could be ready by March. Will we need them?

by admin | Jan 11, 2022 | Breaking News Express-SR

Sorry, this entry is only available in 中文.類型: 連結作者: Berkeley Lovelace Jr. 出處: NBC News 連結:...

Jinhua Qinggan granule, a Chinese herbal medicine against COVID‑19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL‑6 and IFN‑γ: An open‑label, single‑arm pilot study

by admin | Jan 8, 2022 | Chinese and Western Therapeutic Pharmacological Research

Traditional Chinese herbal medicine has provided clinical benefits to patients infected with coronavirus 2019 (COVID‑19) in China. Jinhua Qinggan granule (JHQGG) is a Chinese multi‑herbal formula previously developed for the treatment of H1N1 influenza and has been encouraged for use in patients with clinically suspected COVID‑19 infection. However, the immunopharmacological mechanism for the efficacy of JHQGG has not yet been confirmed. To obtain insight into this issue, the present study examined the acute effects of JHQGG ingestion on hematological and immunological parameters using uninfected individuals as subjects…